Arrhythmia Disorders News

Medtronic announced a recall of all implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillators manufactured after Oct. 13, 2017 with a glassed feedthrough.

In patients with an implantable cardioverter defibrillator for primary prevention, among those with nonischemic cardiomyopathy, Black patients were more likely to have arrhythmias, to receive ICD therapies and to die than white patients.

Levels of omega-3 fatty acids, primarily from diet, were not related to risk for incident atrial fibrillation, according to a meta-analysis published in the Journal of the American College of Cardiology.

Patients with an implantable cardioverter defibrillator and high N-terminal pro-B type natriuretic peptide level have elevated odds of developing a ventricular arrhythmia during follow-up, data show.

Most patients with a new atrial fibrillation diagnosis and an elevated CHA2DS2-VASc score are not prescribed an oral anticoagulant with the first 6 months, contradictory to current guidelines for AF management, researchers reported.

Of the many drug shortages in the U.S. this year, several are used in cardiac emergencies, according to the American Society for Health-System Pharmacists.

AccurKardia announced it received FDA 510(k) clearance for its cloud-based, device-agnostic and automated ECG analysis software for adults aged 22 years and older.

Volunteer responders dispatched to assist people experiencing out-of-hospital cardiac arrest may improve rates of bystander CPR, automated external defibrillator use and 30-day survival, researchers reported.

Biotronik announced the FDA approved its portfolio of pacemakers and cardiac resynchronization therapy pacemakers featuring automatic MRI detection designed to streamline MRI workflow.

Abbott announced that the FDA approved the world’s first dual-chamber leadless pacing system, which will open up leadless pacemaker technology to a broader population.